# PAS-004 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pas-004

> PAS-004, sponsored by Pasithea Therapeutics Corp. (KTTA): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | PAS-004 |
| Codes | PAS-004, CIP-137401 |
| Sponsor | Pasithea Therapeutics Corp. (KTTA) https://sec-api.dev/companies/ktta/catalysts |
| Indications | mapk pathway-driven advanced tumors |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: MAPK pathway-driven advanced tumors.
- First seen 2026-11-13, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001213900-26-119886): "In December 2023, the Company initiated its ongoing Phase 1 open-label, dose escalation trial of PAS-004 in patients with MAPK pathway-driven advanced tumors at sites in the United States and in Eastern Europe." https://www.sec.gov/Archives/edgar/data/1841330/000121390026119886/ea0310948-10q_pasithea.htm
- SEC Form 10-Q (accession 0001213900-26-119886): "In December 2023, we initiated our ongoing Phase 1 open-label, dose escalation trial of PAS-004 in patients with MAPK pathway-driven advanced tumors at sites in the United States and in Eastern Europe." https://www.sec.gov/Archives/edgar/data/1841330/000121390026119886/ea0310948-10q_pasithea.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pas-004.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PAS-004 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pas-004

```bibtex
@misc{secapidev_pdufa_pas_004_20261116,
  title        = {PAS-004 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pas-004}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pas_004_20261116","title":"PAS-004 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pas-004","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
